Heron Therapeutics CFO acquires shares as grants vest

The reported transactions also include shares delivered or withheld for exercise-price or tax-liability payments at $0.28 per share.

Available on EDGAR 11/03/2026 - 12:58 PM EST Accepted by SEC EDGAR 11/03/2026 - 12:54 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Heron Therapeutics, Inc. Executive Vice President and Chief Financial Officer Ira Duarte had 13,535 restricted stock units vest into common shares on October 30, 2026, and 11,695 on October 31, 2026. On those dates, 3,850 and 3,327 common shares, respectively, were delivered or withheld for payment of exercise price or tax liability, each reported at $0.28 per share. No Rule 10b5-1 plan is reported.

The October 30 units were part of 216,562 RSUs granted January 30, 2026, vesting in 16 equal quarterly installments. The October 31 units vest in 16 equal installments beginning one quarter after January 31, 2025.

Insider Trade Summary

25,230 shares exercised/converted

Exercise 6 txns

Insider Duarte Ira

Role EVP, Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units ^F3	11,695	$0.00	$0.00
Exercise	Common Stock ^F1	11,695	--	--
Exercise Price or Tax Liability	Common Stock	3,327	$0.28	$931.56
Exercise	Restricted Stock Units ^F2	13,535	$0.00	$0.00
Exercise	Common Stock ^F1	13,535	--	--
Exercise Price or Tax Liability	Common Stock	3,850	$0.28	$1K

Holdings After Transaction: Restricted Stock Units — 281,206 contracts (Direct); Common Stock — 302,724 shares (Direct)

Holdings Before and After: Restricted Stock Units, 306,436 to 281,206 contracts (Direct); Common Stock, 284,671 to 302,724 shares (Direct)

Footnotes (3)

F1. Each restricted stock unit represents a contingent right to receive one share of common stock.
F2. On January 30, 2026 (the "Date of Grant"), the Reporting Person was granted 216,562 RSUs which vest upon the following time-based vesting schedule: the RSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant.
F3. The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025).

Key Figures

Common shares acquired upon RSU vesting: 13,535 shares Common shares acquired upon RSU vesting: 11,695 shares Shares delivered or withheld for payment: 3,850 shares +4 more

7 metrics

Common shares acquired upon RSU vesting 13,535 shares October 30, 2026

Common shares acquired upon RSU vesting 11,695 shares October 31, 2026

Shares delivered or withheld for payment 3,850 shares October 30, 2026

Shares delivered or withheld for payment 3,327 shares October 31, 2026

Reported per-share price $0.28 per share Code F transactions on October 30 and October 31, 2026

Restricted stock units granted 216,562 RSUs Granted January 30, 2026

Vesting installments 16 equal quarterly installments Schedule for the RSUs granted January 30, 2026

Key Terms

Restricted Stock Units, contingent right, time-based vesting schedule, quarterly installments

4 terms

Restricted Stock Units financial

"Each restricted stock unit represents a contingent right to receive one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right financial

"contingent right to receive one share of common stock"

time-based vesting schedule financial

"vest upon the following time-based vesting schedule"

quarterly installments financial

"vest in 16 equal quarterly installments"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many HRTX shares did CFO Ira Duarte acquire through RSU vesting?

Ira Duarte acquired 13,535 common shares on October 30, 2026, and 11,695 common shares on October 31, 2026, as restricted stock units vested. The units represented contingent rights to receive common shares.

How many HRTX shares were delivered or withheld for payment?

On October 30, 2026, 3,850 common shares were delivered or withheld for payment of exercise price or tax liability; on October 31, 2026, the amount was 3,327 shares. Both transactions were reported at $0.28 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Duarte Ira

(Last)

(First)

(Middle)

25 FENTON MAIN STREET

SUITE 300

(Street)

CARY

NORTH CAROLINA

27511

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
HERON THERAPEUTICS, INC. /DE/ [ HRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/30/2026		M		13,535	A	⁽¹⁾	298,206	D
Common Stock	10/30/2026		F		3,850	D	$0.28	294,356	D
Common Stock	10/31/2026		M		11,695	A	⁽¹⁾	306,051	D
Common Stock	10/31/2026		F		3,327	D	$0.28	302,724	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	$0	10/30/2026		M			13,535	⁽²⁾	⁽²⁾	Common Stock	13,535	$0	175,957	D
Restricted Stock Units	$0	10/31/2026		M			11,695	⁽³⁾	⁽³⁾	Common Stock	11,695	$0	105,249	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of common stock.

2. On January 30, 2026 (the "Date of Grant"), the Reporting Person was granted 216,562 RSUs which vest upon the following time-based vesting schedule: the RSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant.

3. The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025).

	/s/Kathryn Lester Attorney-in-fact for Ira Duarte	11/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR